© 2022 BioMarin. All rights reserved.
Period Ending | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|
Total Revenue | 1,846,275 | 1,860,461 | -- | 1,491,212 |
Cost of Revenue | 470,515 | 524,272 | -- | 315,264 |
Gross Profit | 1,375,760 | 1,336,189 | -- | 1,175,948 |
Operating Expenses | ||||
Research Development | 628,793 | 628,116 | -- | 696,328 |
Selling General and Administrative | 759,375 | 737,700 | -- | 604,353 |
Non Recurring | -- | -- | -- | -- |
Others | 69,933 | 62,200 | -- | 48,791 |
Total Operating Expenses | 1,458,101 | 1,428,016 | -- | 1,349,472 |
Operating Income or Loss | (82,341) | (91,827) | -- | (173,524) |
Income from Continuing Operations | ||||
Total Other Income/Expenses Net | 11,846 | 62,137 | -- | 51,652 |
Earnings Before Interest And Taxes | (60,013) | (13,013) | -- | (102,651) |
Interest Expense | 15,337 | 29,309 | -- | 40,054 |
Income Before Tax | (75,350) | (42,322) | -- | (142,705) |
Income Tax Expense | (11,270) | (901,422) | -- | (65,494) |
Minority Interest | -- | -- | -- | -- |
Net Income From Continuing Ops | (64,080) | 859,100 | -- | (77,211) |
Non-recurring Events | ||||
Discontinued Operations | -- | -- | -- | -- |
Extraordinary Items | -- | -- | -- | -- |
Effect Of Accounting Changes | -- | -- | -- | -- |
Other Items | 0 | 0 | -- | 0 |
Net Income | (64,080) | 859,100 | -- | (77,211) |
Preferred Stock And Other Adjustments | -- | -- | -- | -- |
Net Income Applicable To Common Shares | (64,080) | 859,100 | -- | (77,211) |